Categories
Change Password!
Reset Password!
Tegoprazan and rabeprazole triple therapies achieve comparable H. pylori eradication rates, with no considerable difference in treatment success or safety.
A real-world clinical study has revealed that tegoprazan-based triple therapy offers Helicobacter pylori (H. pylori) eradication rates comparable to rabeprazole-based triple therapy, marking an important update in the field of H. pylori infection treatment, gastric acid suppression therapy, and P-CAB (potassium-competitive acid blocker) research.
Yoon Suk Jung and other researchers reviewed retrospective real-world clinical data from 677 patients who received first-line therapy for H. pylori infection over a two-week treatment duration. Patients were assigned to one of two regimens:
The key endpoint was the H. pylori elimination rate, assessed via intention-to-treat (ITT) and per-protocol (PP) assessment. The findings are depicted in Table 1:
There were no statistically significant differences between tegoprazan and rabeprazole across elimination rates or safety outcomes. The findings confirm that tegoprazan-based triple therapy achieves similar efficacy and tolerability to rabeprazole-based therapy when used as a first-line treatment for H. pylori.
Gut Liver
Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study
Comments (0)